Serratia marcescens

Journal of Medical Microbiology

Volumn 46, Issue 11, 1997, Pages 903-912

  Hejazi, A ^a   Falkiner, F R ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BACTERIOCIN; DISINFECTANT AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; PATHOGENICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SERRATIA MARCESCENS;

EID: 0030817752     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-46-11-903     Document Type: Review

References (123)

1. Sleigh JD, Antibiotic resistance in Serratia marcescens. BMJ 1983; 287: 1651-1653.
2. Gaughran ERL. Division of microbiology from superstition to science: the history of a bacterium. Tran.t NY Acad Sci. The meeting of the division. January 26. 1968.
3. Wheat RP, Zuckerman A, Rantz LA. Infection due to Chromobacteria: report of eleven cases. Arch Intern Mad 1951; 88: 461-466.
4. Dodson WH. Serratia marcescens septicaemia. Arch Intern Med 1968; 121; 145-150.
5. McCormack RC, Kunin CM. Control of a single source nursery endemic due to Serratia marcescens. Pediatrics 1966; 37: 750-755.
6. Alexander RH, Reichenbach DD, Merendino KA. Serratia marcescens endocarditis: a review of the literature and report of a case involving a homograft replacement of the aortic valve. Arch Surg 1969; 98: 287-291.
7. Gouin F, Papazian L, Martin C et al. A non-comparative study of the efficacy and tolerance of cefepimc in combination with amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother 1993; 32 Suppl B: 205-214.
8. Cox CE. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria. Rev Infect Dis 1985; 7 Suppl 4: S767-S770.
9. Körner RJ, Nicol A, Reeves DS, MacGowan AP, Hows J. Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin's lymphoma. J Infect 1994; 29: 73-76.
10. Mills J, Drew D. Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse. Ann Intern Med 1976; 84: 29-35.
11. Cohen PS, Maguire JH, Weinstein L. Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977. Prog Cardiovasc Dis 1980; 22: 205-242.
12. Grimont PAD, Grimont F, Genus VIII. Serratia, In: Krieg NR, Holt JG (eds) Bergey's Manual of systematic bacteriology, vol l. Baltimore, Williams and Wilkins. 1984: 477-484.
13. Pitt TL. State of the art: typing of Serratia marcescens. J Hosp Infect 1982; 3: 9-14.
14. Marrie TJ, Costerton JW. Prolonged survival of Serratia marcescens in chlorhexidine. Appl Environ Mlcmblol 1981; 42: 1093-1102.
15. Parment PA, Ronnerstam R, Walder M. Persistence of Serratia marcescens, Serratia liquefaciens and E. coli in solutions for contact lenses. Acta Opthalmol 1986; 64: 456-462.
16. Nakashima AK, Highsmith AK, Marione WJ. Survival of Serratia marcescens in benzalkonium chloride and in multiple-dose medication vials: relationship to epidemic septic arthritis. J Clin Microbiol 1987; 25: 1019-1021.
17. Szewzyk U, Szewzyk R, Stenström T-A. Growth and survival of Serratia marcescens under aerobic and anaerobic conditions in the presence of materials from blood bags. J Clin Microbiol 1993; 31: 1826-30.
18. Mason CA, Hamer G, Bryers JD. The death and lysis of microorganism in environmental processes. FEMS Microbiol Rev 1986; 39: 373-401.
19. Porter JF, Paton R, Wardlaw AC. Orowth and survival of Bordetella bronchiseptica in natural waters and in buffered saline without added nutrients. Appl Environ Microbiol 1991; 57: 1202-1206.
20. Kolmer JA. Preserved citrated blood "banks" in relation to transfusion in the treatment of disease with special reference to immunologie aspects. Am J Med Sci 1939; 197: 442-452.
21. Gong J, Hogman CF, Hambraeus A, Johansson CS, Eriksson L. Transfusion-associated Serratia marcescens infection: studies of the mechanism of action. Transfusion 1993; 33: 802-808.
22. Hogman CF, Ciong J, Eriksson L, Hambraeus A, Johansson CS. White cells protect donor blood against bacterial contamination. Transfusion 1991; 31: 620-626.
23. Hogman CF, Gong J, Hambraeus A, Johansson CS, Eriksson L, The role of white cells in the transmission of Yersinia enlerocolitica in blood components. Transfusion 1992; 32: 654-657.
24. Gong J, Hogman CF, Hambraeus A, Johansson CS, Eriksson L. Transfusion-transmitted Yersinia enterocolitica infection. Protection through buffy coat removal and failure of the bacteria to grow in platelet-rich or platelet-poor plasma. Vox Sang 1993; 65: 42-46.
25. Hines DA, Saurugger PN, Ihler GM, Benedik MJ. Genetic analysis of extracellular proteins of Serratia mancescens. J Bacterial 1988; 170: 4141-4146.
26. Matsuyama T, Fujita M, Yano I. Wetting agent producing by Serratia marcescens. FEMS Microbiol Lett 1985; 28: 125-129.
27. Matsuyama T, Kaneda K, Nakagawa Y, Isa K, Hara-Hotta H, Yano I. A novel extracellular cyclic lipopeptide which promotes flagellum-dependent und -independent spreading growth of Serratia marcescens. J Bacterial 1992; 174: 1769-1776.
28. Matsuyama T, Murakami T, Fujita M, Fujita S, Yano I. Extracellular vesicle formation and bio-surfactant production by Serratia marcescens. J Gen Microbiol 1986; 132: 865-875.
29. Albert L, Harshey RM. Differentiation of Serratia marcescens 274 into swimmer and swarmer cells. J Bacterial 1990; 172: 4322-4328.
30. O'Rear J, Alberti L, Harshey RM. Mutations that impair swarming motility in Serratia marcescens 274 include but are not limited to those affecting chemotaxis or flagellar function. J Bacterial 1992; 174: 6125-6137.
31. Matsuyama T, Bhasin A, Harshey RM. Mutational analysis of flagellum-independent surface spreading of Serratia marcescens 274 on a low-agar medium. J Bacteriol 1995; 177: 987-991,
32. Rjazantseva IN, Andreeva IN. Ogorodnikova TI. Effect of various growth conditions on pigmentation of Serratia marcescens. Micmbios 1994; 79: 155-161.
33. Alien EG. Conditions of the colour change of prodigiosin. Nature 1967; 216: 929-931.
34. Cho LKN, Lowe IA, Maguire RB, Tsang JC, Relationship of prodigiosin condensing enzyme activity to the biosynthesis of prodigiosin and its precursors in Serratia marcescens. Experientia 1987; 43; 397-399.
35. Akimenko VK, Trutko SM. Physiological role of the oversynthesis of intermediates and the biosynthesis of metabolites for microorganism-producers. Prikl Biokhim Mikrobiol 1991; 27: 17-35.
36. Yu VL. Serratia marcescens: historical perspective and clinical review. N EngI J Med 1979; 300: 887-893.
37. Williams RP, Gott CL, Qadri SMH, Scott RH. Influence of temperature of incubation and type of growth medium on pigmentation in Serratia marcescens. J Bacterial 1971; 106: 438-443.
38. Silverman MP, Munoz EF, Effect of iron and salt on prodigiosin synthesis in Serratia marcescens. J Bacteriol 1973; 114; 999-1006.
39. Feng IS, Webb IW, Tsang IC. Enhancement of sodium dodecyl sulfate of pigment formation in Serratia marcescens OS. Appl Environ Microbiol 1982; 43: 850-854.
40. Williams RP, Gott CL, Qadri SMH. Induction of pigmentation in nonproliferating cells of Serratia marcescens by addition of single amino acids. .J Bacterial 1971; 106: 444-448.
41. Phillips I, King A. Serratia marcescens in hospital practice. Lancet 1977; 1: 538.
42. Ball AR McGhie D, Geddes AM. Serratia marcescens in a general hospital. Q J Med 1977; 46: 63-71.
43. Coria-Jiménez R, Ortiz-Torres C. Aminoglycoside resistance patterns of Serratia marcescens strains of clinical origin. J Epidemiol Infect 1994; 112: 125-131.
44. Carbon C. Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. Scand J Infect Dis 1991; Suppl. 74: 163-172.
45. Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenemhydrolyzing class A ßlactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother 1994; 38: 1262-1270.
46. Nordmann P, Mariette S, Naas T, Labia R, Nicolas MH. Biochemical properties of a carbapenem-hydrolyzing ßlactamase from Enterobacter cloacae and cloning of the gene into Escherichia call. Antimicrob Agents Chemother 1993; 37: 939-946.
47. de Champs C, Henquell C, Guelon D, Sirot D, Gazuy N, Sirot J. Clinical and bacteriological study of nosocomial infections due to Enterobacter aemgenes resistant to imipenem. J Clin Microhiol 1993; 31: 123-127.
48. Ehrhardt AF, Sanders CC, Thomsom K, Watanakunakorn SC, Trujillano-Martin I. Emergence of resistance to imipenem in Enterobacter isolates masquerading as Klebsiella pneumonias during therapy with imipenem/cilastatin. Clin Infect Dis 1993; 17: 120-122.
49. Livermore DM. Carbapenemases. J Antimicrob Chemother 1992; 29: 609-613.
50. Palomar J, Puig M, Montilla R, Loren JG, Vinas M. Lipopolysaccharide recovery restores susceptibility levels towards ß-lactamase in Serratia marcescens. Microbios 1995; 82: 21-26.
51. imp among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995; 39: 824-829.
52. Osano E, Arakawa Y, Wacharotayankun R et al. Molecular characterization of an enterobacterial metallo ß-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother 1994; 38: 71-78.
53. Naas T, Livermore DM, Nordmann P. Characterization of an LysR family protein SmeR from Serratia marcescens S6, its effect on expression of the carbapenem-hydrolyzing ßlactamase Sme-1, and comparison of this regulator with other ß-lactamase regulators. Antimicrob Agents Chemother 1995; 39: 629-637.
54. Bellido F, Pechère J-C, Hancock REW. Novel method for measurement of outer membrane permeability to new ßlactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991; 35: 68-72.
55. Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34: 337-342.
56. Chong Y, Lee K, Kwon OH. In-vitro activities of cefepime against Enterobacter cloacae. Serratia marcescens, Pseudomonas aeruginosa and other aerobic Gram-negative bacilli. J Antimicrob Chemother 1993; 32 Suppl. B: 21-29.
57. Platt DJ, Sommerville JS. Serratia species isolated from patients in a general hospital. J Hasp Infect 1981; 2: 341-348.
58. Garcia DC, Woloj GM, Pifieiro S, Sordelli DO, Kaufman S. An 8-year study of resistance to amikacin in gram-negative bacilli isolates from patients with nosocomial infections at one hospital in Argentina. J Med Microbiol 1995; 42: 283-290.
59. Juvin ME, Potel G, Caillon J et al. In vivo bactericidal activities of ciprofloxacin and pefloxacin in an experimental model of Serratia marcescens endocarditis. Anttmicroh Agents Chemother 1994; 38: 883-885.
60. Reid G, Sobel JD. Bacterial adherence in the pathogenesis of urinary tract infection: a review. Rev Infect Dis 1987; 9: 470-487.
61. Yamamoto T, Ariyoshi A, Amako K. Fimbria-mediated adherence of Serratia marcescens US5 strain to human urinary bladder surface. Microhiol Immunol 1985; 29: 677-681.
62. Glauser MP, Lyons JM, Braude AI. Prevention of chronic experimental pyelonephritis by suppression of acute suppuration. J Clin Invest 1978; 61: 403-407.
63. Slotki IN, Asscher AW. Prevention of scarring in experimental pyelonephritis in the rat by early antibiotic therapy. Nephron 1982; 30: 262-268.
64. Bille J, Glauser MP. Protection against chronic pyelonephritis in rats by suppression of acute suppuration: effect of colchicine and neutropenia. J Infect Dis 1982; 146: 220-226.
65. Mizunoe Y, Matsumoto T, Haraoka M, Sakumoto M, Kubo S, Kumazawa J. Effect of pili of Serratia marcescens on Superoxide production and phagocytosis of human polymorphonuclear leukocytes. J Ural 1995; 154: 1227-1230.
66. Mudd S, Mudd EBH. The penetration of bacteria through capillary spaces. IV. A kinetic mechanism in interfaces. J Exp Med 1924; 40: 633-645.
67. Ashkenazi S, Weiss E, Drucker MM. Bacterial adherence to intravenous catheters and needles and its influence by cannula type and bacterial surface hydrophobicity. J Lab Clin Med 1986; 107: 136-140.
68. Ness-Greenstein RB, Rosenberg M, Doyle RJ, Kaplan N. DNA from Serratia marcescens confers a hydrophobic character in Escherichia coli. FEMS Microbiol Lett 1995; 125: 71-75.
69. Rosenberg M, Blumberger Y, Judes H, Bar-Ness R, Rubinstein E, Mazor Y. Cell surface hydrophobicity of pigmented and nonpigmented clinical Serratia marcescens strains. Infect Immun 1986; 51: 932-935.
70. Goldberg S, Doyle RJ, Rosenberg M. Mechanism of enhancement of microbiol cell hydrophobicity by cationie polymers. J Bacterial 1990; 172: 5650-5654.
71. Goldberg S, Konis Y, Rosenberg M. Effect of cetylpyridinium chloride on microbial adhesion to hexadecane. Appl Environ Microbiol 1990; 56: 1678-1682.
72. Palomar J, Leranoz AM, Vinas M. Serralia marcexcens adherence: the effect of O-antigen presence. Microhins 1995; 81: 107-113.
73. Joiner KA. Studies on the mechanism of bacterial resistance to complement-mediated killing and the mechanism of action of bactericidal antibody. Curr Top Microbiol Immunol 1985; 121: 99-133.
74. Oxley D, Wilkinson SG. Structures of neutral glycans isolated from the lipopolysaccharides of reference strains for Serratia marcescens serogroups O16 and O20. Carbohydr Res 1989; 193: 241-248.
75. Szabo M, Bronner D, Whitfield C. Relationship between rfb gene clusters required for biosynthesis of identical Dgalactose-containing O antigens in Klebsiella pneumoniae serotype Ol and Serratia marcescens serotype 016. J Bacterial 1995; 177: 1544-1553.
76. Straus DC, Atkisson DL, Garner CW. Importance of a lipopolysaccharide-containing extracellular toxic complex in infections produced by Klebsiella pneumoniae. Infect Immun 1985; 50: 787-795.
77. Palomar J, Montilla R, Fuste MC, Vinas M. The role of 0antigen in susceptibility of Serratia marcescens to nonimmune serum. Microbios 1993; 76: 189-196.
78. Palomar J. El Lipopolysaccharido de Serratia marcescens como factor de virulencia. PhD thesis, University of Barcelona. 1994.
79. Gaston MA, Pitt TL. O-antigen specificities of the serotype strains of Serratia marcescens. J Clin Microbiol 1989; 27: 2697-2701.
80. Fuchs RL, McPherson SA, Drahos DJ. Cloning of a Serratia marcescens gene encoding chitinase. Appl Environ Microbiol 1986; 51: 504-509.
81. Monreal J, Reese ET. The chitinase of Serratia marcescens. Can J Microbiol 1969; 15: 689-696.
82. Brurberg MB, Haandrikman AJ, Leenhouts KJ, Venema G, Nes IF. Expression of chitinase gene from Serratia marcescens in Lactococcus lactis and Lactobacillus plantarum. Appl Microbiol Biotechnol 1994; 42: 108-115.
83. Sundheim L, Poplawsky AR, Ellingboe AH. Molecular cloning of two chitinase genes from Serratia marcescens and their expression in Pseudomonas species. Phys Mol Plant Pathol 1988; 33: 483-491.
84. Brurberg MB, Eijsink VGH, Nes IK Characterization of a chitinase gene (chi A) from Serratia marcescens BJL 200 and one-step purification of the gene product, FEMS Microbiol Lett 1994; 124: 399-404.
85. Akotsuka H, Kawai E, Omori K, Shibatani T. The three genes lipB, lipC, and lipD involved in the extraccullular secretion of the Serratia marcescens lipase which lacks an N-tcrminal signal peptide. J Bacteriol 1995; 177: 6381 6389.
86. Burd W. Yourkevieh O, Voskoboev AJ, van Pée KH. Purification and properties of a non-haem chloroperoxidase from Serratia marcescens. FEMS Microbiol Lett 1995; 129: 255-260.
87. Turner WB. Nitro compounds. In: Laskin AI. Lechevalier HA (eds) CRC Handbook of microbiology, vol 3. Cleveland, CRC Press. 1973: 445-447.
88. Létoflé S, Ghigo J-M, Wandersman C. Identification of two components of the Serratiu marcescens metalloprotease transporter: protease SM secretion in Escherichia coli is TolC dependent. J Bacteriol 1993; 175: 7321-7328.
89. Létoffé S. Cihigo J-M, Wandcrsman C. Secretion of the Serratia marcescens HasA protein by an ABC transporter. J Bacterial 1994; 176: 5372-5377.
90. Larose P, Picard B, Thibault M, Grimont F', Goullet P. Nosocomial Serratia marcescens individualized by five typing methods in a regional hospital. J Hosp Infect 1990; 15: 167-172.
91. Chctoui H, Delhalle E, Osterrieth P, Rousseaux D. Ribotyping for use in studying molecular epidemiology of Serratia marcescens: comparison with biotyping. J Clin Microbiol 1995; 33: 2637-2642.
92. Bingen EH, Mariani-Kurkdjian P, Lambert-Zeehovsky NY et al, Ribotyping provides efficient differentiation of nosocomial Strratlu marcescens isolates in a pacdiatric hospital. J Clin Microbiol 1992; 30: 2088-2091.
93. Alonso R, Aucken HM, Perez-Diaz JC, Cookson BD, Baquero F, Pitt TL. Comparison of serotype, biotype and baeteriocin type with rDNA RFLP patterns for the type identification of Serratia marcescens. Epidemiol Infect 1993; 111: 99-107.
94. Picard B, Bruncau B, Goullet P. Demonstration of an outbreak of Serratia marcescens infections in medical intensive care unit by esterase electrophoretic typing. J Hosp Inject 1988; 11: 194-195.
95. Liu PY-F, Lau Y-J, Hu B-S et al. Use of PCR to study epidemiology of Serratiu marcescens isolates in nosocomial infection. J Clin Micmhiol 1994; 32: 1935-1938.
96. Grimont PAD, Grimont F. Biotyping of Serratia marcescens and its use for epidemiological studies. J Clin Microbiol 1978; 8: 73-83.
97. Grimont F, Grimont PAD. Ribosomal ribonucleic acid gene restriction patterns as potential taxonomic tools. Ann lnst Pasteur/Microbiol 1986; 137B: 165-175.
98. Pitt TL, Erdman YJ. Serological typing of Serratia marcescens. Methods Micmhiol 1984; 15: 173-211.
99. Traub WH. Serotyping of Serratiu marcescens: identification of a new O-antigen (O24). Zentralbl Bakteriol Mikrobiol HygA 1985; 259: 485-488.
100. Gaston MA, Pitt TL. Improved 0-scrotyping method for Serratia marcescens. J Clin Micmhiol 1989; 27: 2702-2705,
101. Traub WH. Serotyping of Serratia marcescens: detection of two new 0-antigcns (025 and O26). Int J Med Micribiol 1991; 275: 495-499.
102. Aucken HM, Merkouroglou M, Miller AW, Galbraith L, Wilkinson SG. Structural and serological studies of lipopolysaccharides from proposed new serotypes (025 and O26) of Serratia marcescens. FEMS Microbiol Lett 1995; 130: 267-272.
103. Bosi C, Davin-Regli A, Charrel R, Rocca B, Monnet D, Bollet C. Serratia marcescens nosocomial outbreak due to contamination of hexetidine solution. J Hosp Infect 1996; 33: 217-224.
104. Williams JGK, Kubclik AR, Livuk KJ, Rafalski JA, Tingey SV. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers, Nucleic Acids Res 1990; 18: 6531-6535.
105. Woods CR, Versalovic J, Koeuth T, Lupski JR. Analysis of relationships among isolates of Citrobacter divverses by using DNA fingerprints generated by repetitive sequence-based primers in the polymerase chain reaction. J Clin Microbiol 1992; 30: 2921 2929.
106. Wilfert JN, Barrett KF. Kass EH. Bacteremia due to Serratia marcescens. N Engt J Med 1968; 279: 286-289.
107. Davis JT, Foiltz E, Blakemore WS, Serrtia marceacena. A pathogen of increasing clinical importance. JAMA 1970; 214: 2190-2192.
108. Wilkowske CJ, Washington JA, Martin WJ, Ritts RE, Srrratia marescens. Biomedical characteristics, antibiotic susceptibility patterns, and clinical significance. JAMA 1970; 214: 2157-2162.
109. Nakashima AK, McCarthy MA, Marione WJ, Anderson RL. Epidemic septic arthritis caused by Serratia marescens and associated with a benzalkonium chloride antiseptic. Clin Microbiol 1987; 25: 1014-1018.
110. Sautter RL, Mailman KH, Legaspi RC. Serratia marcescens meningitis associated with contaminated benzalkonium chloride solution. Infect Control 1984; 5: 223-225,
111. Ehrenkranz NJ, Bolyard EA, Wiener M, Cleary TJ. Antibiotic-sensitive Serratia marcescenx infections complicating cardiopulmonary operations: contaminated disinfectant as a reservoir. Lancet 1980; 2: 1289-1292.
112. Barry MA. Craven DE, Goularte TA, Lichtenberg DA. Serratia marcescens contamination of antiseptic soap containing trielosan: implications for nosocomial infection, Infect Control 1984; 5: 427- 430.
113. Meers PD, Ayliffe GA, Emmerson AM el al. National survey of infection in hospitals 1980. Part 2: Urinary tract infection. J Hosp Infect 1981; 2: 23-28.
114. Suryaprakash B, Rao MS, Panigrahi D. Vaidyanathan S, Goel AK. Ayyagari A, Formalin in the urinary bag: a cheap measure to control infection in urology wards. Lancet 1984; 2: 104-105.
115. Thompson RL, Haley CE, Searcy MA el al. Catheterassociated bacteriuria: failure to reduce attack rates using periodic instillations of a disinfectant into urinary drainage systems. JAMA 1984; 251: 747-751.
116. Christensen GD, Korones SB, Reed L, Bulley R, McLaughlin B, Bisno AL. Epidemic Serratia marcescens in a neonatal intensive care unit: importance of the gastrointestinal tract as a reservoir. Infect Control 1982; 3: 127-133,
117. Lewis DA, Hawkey PM, Watts JA et al. Infection with netilmicin resistant Sarratia marcescens in a special care baby unit, BMJ 1983; 287: 1701-1705.
118. Heltberg O, Skov F, Gerner-Smidt P et al. Nosocomial epidemic of Serratia marcesens septicemia ascribed to contaminated blood transfusion bags. Transfusion 1993; 33: 221 -227.
119. Hogman CF, Fritz H, Sandberg L, Posttransfusion Serratia marcescens septicemia. Transfusion 1993; 33: 189-191.
120. Jeppsson B, Lindahl S, Ingemansson S, Kornhall S, Sjoval S. Bacterial contamination of blood transfusion: an unusual cause of sepsis. Acta Chir Scand 1984; 150: 489-491.
121. Woodfield DO. Transfusion acquired Serratia liqitejaciens septicaemia. N Z Med J 1991; 104: 141.
122. Hawkey PM. Constable HK. Selection of netilmicin resistance, associated with increased 6' aminoglycoside acetyltransfcrase activity, in Serratia marcescens. J Antimicrob Chemother 1988; 21: 535-544.
123. Hejazi A. Keane CT, Falkiner FR. The use of RAPD-PCR as a typing method for Serratia marcescens. J Med Microbiol 1997; 46: 913-919.